Loading...
XNASAPVO
Market cap2mUSD
Dec 24, Last price  
4.84USD
1D
2.76%
1Q
2,606.94%
Jan 2017
-85.83%
IPO
-88.08%
Name

Aptevo Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:APVO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
50.07%
Rev. gr., 5y
-26.64%
Revenues
0k
-100.00%
170,00045,631,00033,601,00036,434,00014,658,00023,067,00032,424,0004,309,00012,292,0003,114,0000
Net income
-17m
L
-53,337,000-51,115,000-59,317,000-112,415,0006,973,000-53,689,000-40,448,000-18,448,000-27,313,00042,669,000-17,411,000
CFO
-12m
L-44.20%
-51,392,000-47,007,000-48,760,000-36,862,000-41,573,000-51,422,000-42,383,000-29,318,000-21,679,000-21,022,000-11,730,000
Earnings
Mar 03, 2025

Profile

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
URL
http://aptevotherapeutics.com/
IPO date
Jul 20, 2016
Employees
45
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,114
-74.67%
12,292
185.26%
Cost of revenue
29,445
32,656
52,686
Unusual Expense (Income)
NOPBT
(29,445)
(29,542)
(40,394)
NOPBT Margin
Operating Taxes
(35,655)
(2,095)
Tax Rate
NOPAT
(29,445)
6,113
(38,299)
Net income
(17,411)
-140.80%
42,669
-256.22%
(27,313)
48.05%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,428
6,930
21,671
BB yield
-12,772.00%
-2,575.61%
-2,584.49%
Debt
Debt current
2,000
11,667
Long-term debt
10,794
13,614
6,389
Deferred revenue
Other long-term liabilities
15,580
Net debt
(6,110)
(7,021)
(26,988)
Cash flow
Cash from operating activities
(11,730)
(21,022)
(21,679)
CAPEX
(29)
(713)
Cash from investing activities
(29)
(713)
Cash from financing activities
5,998
(2,616)
26,161
FCF
(28,456)
3,311
(36,725)
Balance
Cash
16,904
22,635
45,044
Long term investments
Excess cash
16,904
22,479
44,429
Stockholders' equity
(223,386)
(205,988)
(214,016)
Invested Capital
241,004
233,497
247,527
ROIC
2.54%
ROCE
EV
Common stock shares outstanding
278
116
107
Price
0.18
-92.20%
2.32
-70.52%
7.87
-78.53%
Market cap
50
-81.29%
269
-67.91%
839
-70.31%
EV
(6,060)
(6,752)
(26,149)
EBITDA
(28,878)
(28,641)
(39,250)
EV/EBITDA
0.21
0.24
0.67
Interest
35,655
Interest/NOPBT